Cargando…
Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?
Autores principales: | Chan, Chilam, Lustig, Marta, Baumann, Niklas, Valerius, Thomas, van Tetering, Geert, Leusen, Jeanette H. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514090/ https://www.ncbi.nlm.nih.gov/pubmed/36177025 http://dx.doi.org/10.3389/fimmu.2022.1017924 |
Ejemplares similares
-
Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?
por: Chan, Chilam, et al.
Publicado: (2022) -
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
por: van Tetering, Geert, et al.
Publicado: (2020) -
Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9
por: Chan, Chilam, et al.
Publicado: (2023) -
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
por: Baumann, Niklas, et al.
Publicado: (2022) -
IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)